Polan Tablet

Polan Dihydrochloride is a preparation of Polan Dihydrochloride. Polan is the active (levo) isomer of Cetirizine. It is a new highly effective and well-tolerated non-sedating antihistamine with potent antiallergic properties. It has a two-fold higher affinity for H1-receptors than Cetirizine. Polan has a rapid and long-lasting action, allowing once-a-day administration.


Polan Dihydrochloride is used for the treatment of symptoms associated with allergic conditions such as seasonal allergic rhinitis, perennial allergic rhinitis and chronic idiopathic urticaria.

Polan is also used to associated treatment for these conditions: Allergic Rhinitis (AR), Chronic Idiopathic Urticaria, Common Cold, Nasal Congestion, Perennial Allergic Rhinitis (PAR), Seasonal Allergic Rhinitis


Trade Name Polan
Generic Levocetirizine
Levocetirizine Other Names Levocetirizina, Levocetirizine
Weight 5mg
Type Tablet
Formula C21H25ClN2O3
Weight Average: 388.89
Monoisotopic: 388.1553704
Protein binding

Plasma protein binding of levocetirizine was on average 96.1% 1 hour post dose and 91.9% 6 hours post dose.

Therapeutic Class Non-sedating antihistamines
Manufacturer Globe Pharmaceuticals Limited
Available Country Bangladesh
Last Updated: June 23, 2021 at 11:22 am


Levocetirizine Structure


Polan dosage

Adults and children 12 years of age and older: 5 mg once daily in the evening

Children 6 to 11 years of age: 2.5 mg once daily in the evening

Children 6 months to 5 years of age: 1.25 mg (1/2 teaspoon oral solution) once daily in the evening

Renal Impairment: Adjust the dose in patients 12 years of age and older with decreased renal function

Side Effects

The most common adverse reactions (rate ≥2% and > placebo) were somnolence, nasopharyngitis, fatigue, dry mouth, and pharyngitis in subjects 12 years of age and older, and pyrexia, somnolence, cough, and epistaxis in children 6 to 12 years of age. In subjects 1 to 5 years of age, the most common adverse reactions (rate ≥2% and > placebo) were pyrexia, diarrhea, vomiting, and otitis media. In subjects 6 to 11 months of age, the most common adverse reactions (rate ≥3% and > placebo) were diarrhea and constipation.


Epileptic patients and patients at risk of convulsions. Renal impairment. Pregnancy and lactation.

Food Interaction

  • Avoid alcohol.
  • Take with or without food.

Volume of Distribution

The volume of distribution of levocetirizine is 0.33±0.02L/kg.

Half Life

The average half life of levocetirizine is 7.05±1.54 hours.


The average clearance of levocetirizine is 0.57±0.18mL/min/kg.

Pregnancy & Breastfeeding use

Pregnancy: The safety of Polan in pregnancy has not been established. Therefore, it should be used with caution during pregnancy and only if the potential benefits to the mother outweigh any risks to the foetus.

Lactation: Polan passes into breast milk. So, it should be used with caution in nursing mothers and only if the expected benefit to the mother is greater than the risk to the nursing infant.


It is contraindicated in patients who are hypersensitive to this medication or to any of its ingredients.

Special Warning

Paediatric use: Not recommended for use in children less than 6 years of age.

Acute Overdose

Symptoms: Drowsiness, agitation, restlessness, confusion, diarrhoea, dizziness, fatigue, headache, malaise, mydriasis, pruritus, sedation, somnolence, stupor, tachycardia, tremor and urinary retention. 

Management: Symptomatic and supportive treatment. Gastric lavage must be considered shortly following ingestion.

Storage Condition

Store between 20-25°C.

Innovators Monograph

Polan contains Levocetirizine see full prescribing information from innovator // generic/levocetirizine/levocetirizine-dihydrochloride-prescribing-information" Monograph